The BRCA1 mutation is an actionable mutation for the treatment of breast cancer, as PARP inhibitors are approved for patients with metastatic breast cancer who harbor germline mutations in BRCA1 and BRCA2. Other biomarkers associated with targeted therapies for breast cancer include:
PIK3CA activating mutation
BRAF, C-KIT, and KRAS2 are mutations associated with targeted therapies in malignancies other than breast cancer.
For additional information, refer to the guidelines from the National Comprehensive Cancer Network (NCCN), the guidelines from the American Society of Clinical Oncology (ASCO), and the guidelines from the European Society for Medical Oncology (ESMO).
Learn more about targeted therapies for breast cancer.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Pavani Chalasani. Fast Five Quiz: Breast Cancer Treatment - Medscape - Jul 12, 2021.